Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It would seem logical that the shares issue for the cancer deal and shares that got returned to the treasury because the deal didn’t happen.
We should know tomorrow 5/22 when the 1st Q report is due...
as far as what NDTP has and who has it.
I Agree - the 1st Q report will tell us more
Should be here early this week coming up?
Well, it is progress and a positive step. How big is yet to be determined, but a lot more good things can happen with the CE removed than with it in effect.
Wow! Then CE removal is the final piece. With a 5/22 Q1 and an on-time 2022 annual by no later than 5/31 we could be back in business and out of hell. Game changer if this happens.
Bivins, did your other CE stocks pump upon the CE removal?
Progress!
This is my only CE but I have noticed that a few tickers have managed to get it removed over the past few weeks/months.
The CEO has filed a notice of late filing with OTCMARKETS
in regard with 1st Q results.
So we will see some financials soon and maybe figure out where 155M shares went to.
NDTP pink current today on OTC Marktes
After reading your post, you are right.
You are the man!
Be careful what you wish for on removal of the CE, because without an operating business, revenue and net profits, a huge pile of cash, NDTP Nano tech licensee and upfront income on the Tech asset, and a real public business plan and a real experienced, Bio-medical Nano tech, SEC reporting experienced and experienced CEO and management team in place with a working website... once the CE and EM are gone the Insiders can dump their insider shares on us retail, and right now we have no F*cking Clue (Proof, or explanation) who got the 150 Mil new shares or why or what they were for, or what we got for the massive dilution.
I am looking for either 3/4 Billion dollars of real value for those shares, or a return of those shares, or most of them, based on a minimum share price / value of at least $10/share.
I suggest everyone re-read this post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171849754
Also, note that the CE puts pressure on the NDTP insiders, as they have been invested for 10 years with no exit, yet. The CE protects us from any insider dumping of shares to the float, to the Canadians for chump change. I am perfectly OK with that, because it puts the pressure on the insiders to hurry and get this ready for real operation and business and a share price rally.
I am 99% sure I discovered the real reason for the first 2 years of delay here, but I will keep that to myself unless it is announced someday by the company. But I will say this. The Pandemic and 100% refocus and lack of FDA resources and manpower and ...................... to do the normal job of the FDA, sidelined just about everything for 2 years that was not Covid and vaccine and Covid testing related. By the time the FDA turned the phone back on, The founder and largest shareholder, was incapacitated by strokes from what I heard. That was kind of confirmed when he was replaced last spring.
Then 4-5 months later Dr. Mark Kester had the gall to die on us... I mean, what was he thinking? Did he not know we were counting on him?? (JK)
Then 8 weeks ago, Mr P, tried a Nasdaq EU save and exit, that was so bad we killed it. Management listed to us, a first? And a win for us.
Now Mr P/CEO has had just weeks to regroup, and start over, and he did at least get rid of the tacky Shell tag, that was something even I did not expect, not bad for an old race horse in his 70s?
The next filing may be very interesting. At least they got the (-) and (+) signs right on the financials finally . PROGRESS LOL
I will say this one more time. The fact that no one, not the CEO or Insiders have asked for my ideas for tech or people to replace Hovis or Dr. Mark Kester, tells me they are confident they can find and pick the right people, one like Dr. Kester that has a long life span programmed into his or her DNA? They had the savvy and skills and the right stuff to score bringing in Dr. Mark Kester. They can find another one.
And the recent parade of news, research papers and spin off success stories of Dr. Mark Kester's work,
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171849754
tells me some of his world wide research associates and students are likely suspects that the NDTP insiders/and CEO should be tapping for ideas.
They also need to fix, execute/severely reduce most of that 150 Mil new mystery share lot, or prove it is worth 3/4 Billion dollars of NDTP shares.
We will see what the latest spin is in the pending quarterly.
I agree with you. I emailed the email address and asked for info - and got ZERO reply. Not even a "I can't talk to you right now" reply.
Frustrating.
I appreciate all he did to get the shell in the state it is now, but we need to move forward. Having this anchor of CE around our necks stops this issue from being actively traded - and therefore limits its appreciation to something close to Zero.
We're both in IFUS now and I see that as realizing $$$ more quickly.
My guess is the super voting share was a way for the insiders to give Passalaqua ultimate bargaining power with the Swiss company. We need confirmation of that but it's possible Passalaqua took back his original 3.9 million restricted shares for that one SVS, so it might have been retired.
Unfortunately there is way more we don't know than what we do know. Bad time to have a CEO that either can't or won't communicate with us.
I would really like to give Passalaqua the benefit of the doubt. He did one hell of a job getting this shell ready for Hovis, et al. And he couldn't have known what was coming for Hovis and Kester. I would also like him to know how fiercely loyal and passionate the 65 or so common shareholders are for this company. How our group owns more than half of the 292,000 common shares, and if we're given the opportunity, we can run this stock hard if given real, non-hype news of something really solid. But i don't know if he knows any of that.
I share Chase's frustration about the lack of communication. Even if we wanted to take over the company - the "Super Share vote" has us over a barrel.
I quite frankly don't know what to do but wait with this issue.
NOT HAPPY!
I can't speak for others but all i've heard for going on three years now is excuses. The pandemic slowed us down, Hovis got sick and couldn't file on time, Kester died. Well of course he died. We will all die before anything happens here at this rate of snail movement.
No more dang excuses. Somehow a million different companies didn't let the pandemic crush their company. Many companies survive the illness of their CEO. And companies get past the death of their Key Man.
First things first. We need to confirm if we have any tech left. Have the 11 non-Passalaqua insiders departed and taken the CCA/UPenn Med tech with them? If so, who is our new 155 million share daddy? If not, who remains? And do we have any expection of an on-time Q1 filing, an on-time 2022 annual report, and an end to CE/Pink limited hell? If the answer is no then we are in massive trouble, and we need to find somone or someones who are prepared to do the necessary work. Unfortunately for the commom shareholders it doesn't appear as if Passalaqua plans to communicate with us, except perhaps through the filings which, unfortunately, may not be released on time.
I'd say we are at least 6 to 12 months from losing our CE designation, and that's if we start now with total OTC compliance and audited financials. Let's see if we can walk and chew gum first, starting with an on-time Q1 filing to show the OTC we have a g&d da$n pulse.
Only one thing matters in the short term: getting that dang CE removed and becoming pink current. Without those two we are dead in the water.
Passalaqua better file the Q1 on time or i believe it's bed time for bonzo. A late filing would be a swift kick to the crotch of the common shareholders.
I will pay for audited financials out of my own pocket if Passalaqua turns over the keys to the Thunderbird to me and a group of key common shareholders, and we will get this company out of CE hell. I'm no biotech guy, but i can run a company as long as it takes to get a young, hungry executive into the hot seat. Unless you're up for the challenge, Mike? You've got the tech side covered and you have connections in this field.
Let's do this.
I am still hopeful for this issue!
The applications of this technology are too numerous to list here, and any one of them could be a game changer.
This CE has really been a damper - and it needs to go.
Well the elves of NDTP (Insiders) have been very quiet before, and surprised us with the arrival of the Gold standard of the nano tech world, Dr. Mark Kester who even from the grave made news again, today (1).
When they did that, it was proof that NDTP insiders had/have the right stuff to attract one the few geniuses in the Nano tech drug, delivery of stuff nano tech world to $NDTP. If they did it before, they can do it again.
I do not mind waiting a bit longer if it means they pull off that kind of coup again, and get us the right people with the right skills in place to move $NDTP forward.
I would prefer they work smart, rather than hard....
Here is the news today, which shows once more what a Giant Dr. Mark Kester was in this field (1) (He will no doubt be missed, by many):
https://news.virginia.edu/content/youngkins-support-uva-born-company-announces-new-charlottesville-plant
"
Identifying a problem, then finding a solution has been the genesis for countless startup companies.
That’s what makes Payam Pourtaheri and Ameer Shakeel’s entrepreneurial journey so unique. As undergraduate students in the University of Virginia’s School of Engineering and Applied Science seven years ago, they did just the opposite.
Working in the lab of UVA pharmacology professor Mark Kester, Pourtaheri and Shakeel created a bioparticle capable of breaking down a wide range of substances.
There was just one problem.
(UVA pharmacology professor Mark Kester, who died in August, was an AgroSpheres cofounder. (Dan Addison, University Communications) )
“We were excited by our platform technology and its potential, but we did not know the best use case for it,” Pourtaheri recalled. “We were basically looking for a problem to solve with a solution in hand.”
Kester advised Pourtaheri and Shakeel to prove their technology by “going after some low-hanging fruit” – and that is literally what they did.
Pourtaheri and Shakeel began testing their technology on grapes at local vineyards, and soon after decided that trying to safely degrade the harmful pesticides on crops would be the best application.
In 2016, AgroSpheres was born. Today, the company – which obtained one of its patents through the UVA Licensing & Ventures Group, and last year announced a multi-year collaboration with Bayer to create novel modalities of biologicals for use as crop protection products – is thriving.
On Thursday afternoon, Pourtaheri and Shakeel – with Virginia Gov. Glenn Youngkin in attendance – announced plans to build a pilot fermentation plant in a building near their company headquarters on Seminole Trail in Charlottesville. They will do so using $25 million from a recent AgroSpheres investment round.
“The milestone that we are celebrating today is tremendous – a $25 million investment to expand in Albemarle County, creating 53 spectacular, high-paying jobs in order to increase production space, constructing a research and development facility and a demonstration facility for new products,” Youngkin said. “All right here. Really awesome.”"
"“Enhanced shelf-life and field-stability make it so that any farmer can use the technology with their existing equipment,” Pourtaheri said.
Added Shakeel: “Our vision is local manufacturing, but global impact. Our farmers in Charlottesville can use these products; our farmers in southeast Asia can use these products.”
Looking into the future, Pourtaheri and Shakeel – who were selected to Forbes’ “30 Under 30” list in 2021 – said they hope AgroSpheres will become a leader in transitioning the crop protection and nutrition space to environmentally friendly practices. "
"Already, the company has raised roughly $40 million in investments and grants and has built a diverse and dynamic team.
“We are excited to invest in growing the biotech hub here in Charlottesville,” Pourtaheri said.
Pourtaheri said it’s been a fun and humbling journey coming from a small bench in professor Mark Kester’s lab. He said AgroSpheres is forever grateful to Kester, a co-founder who died unexpectedly last August.
“If you knew Mark … he would have been bouncing off the walls telling [people] that the governor is coming to see his boys,” Pourtaheri said. “We’re missing him a little bit more today. He really encouraged us to get out there.”
*******
My thoughts: Dr. Mark Kester had many students over the decades and associates, and there must be many contacts and associates at UPennMed and the two (or 3?) Universities Dr. Mark Kester the original $NDTP tech (Univ of So. Florida) came out of, and others that could bring great combinations of ready to use or combine-able with NDTP NPC-Nano Tech Nano tech to $NDTP.
We should see a Quarterly filing this month, and I hope to see clarity on the 150 Mil mystery shares, at least....
The fact no one at NDTP has replied to me, tells me they do not think they need my help...Even though I offered it...free of charge...as an activist outsider shareholder...
I also suspect the recent bank failures, and soaring interest rates and US Debt ceiling brick wall Washington is heading into this month, are not helping, just as the Pandemic a million plus US deaths, and the death of Dr. Mark Kester, and loss (too ill to run the company.... the last 14 months or so?) of Hovis, did not help....
Sure hope management is working hard behind the scenes here. Sure is quiet.
Answer is the current CEO is not a Biotech/Drug PhD/MD published research genius or drink line genius, or Nasdaq quality Billion dollar company CEO grade level person, IMO. He is in his mid 70's and trying to help save the company. He was a shell finder, used by Hovis to find and acquire a clean shell. Because of the 100% lack of communication, he may not have any clue that we were serious hard core retail investors. He knows, now, LOL
With Dr. Michael Fountain retired, Dr Mark Kester dead (that had to be a shock to their plans) , Hovis likely has brain damage (strokes), they need time to romance the right team and CEO, and deals now....
Dr. Mark Kester, per the recent updated from the current CEO, was in fact, as I had speculated here, bringing the Nano-Ceramide Cancer technology to NDTP.
IMO it could have been combined with the original NDTP BBB Blood Brain Barrier crossing Nano-Loposome tech to deliver a whole new cancer tech to brain cancer, something that no one has done before. Or at least Dr. Kester could have brought the original TBI Traumatic Brain Injury reversal technology and products to life..
There are other Fountains and Kesters out there. I know some of them.
But the insiders that funded this Hovis-UPennMed R&D going back to 2013, That started with the Hovis drink line ideas and Dr. M. Fountain overseen R&D, funded by the DOD/DARPA/Pentagon/USArmy/NIH grants at the University of So Florida in 2010, was the start of all of this, and it is still viable, with the right management people at the helm.
Romancing and hiring a new team, with the kind of credentials we need, does not happen over night. Or in just a few weeks... They have many options for moving forward. At this stage, one does not rush things, finding a new CEO and Dr. Mark Kester to make a deal, is not something one wants to rush (And screw up, by rushing it).
Also keep in mind, the CE, protects us retail, from insider share dumps, before the stadium lights go on and the full business is up and running, with a real Nasdaq quality CEO, and drug and/or drink line production and marketing staff...
This CEO would be smart to open the door to deal making discussions with ex-Dr. Kester research associates, co-authors and his understudies (Many who just released published papers, as recently as last month, covering work they worked with Dr. Mark Kester on) , and his Keystone Partner that is still running a private Biotech, Pen-something(?) firm, that took most of the Keystone Pharma assets last year into a new company name, I would need to dig up my earlier DD..., but if I was the $NDTP CEO right now, I would be researching opportunities, people, resumes, patents, combinations of nano-Drug and or drink line options... Question is, does this CEO know how to do that, a guy in his mid 70s?
Or or one or more of the remaining founders working on romancing the next Dr. Mark Kester??? I would....., but I am sure they have way more top end connections than I do, which is why I got into this stock in the first place..
Just not sure this CEO knows how to do that?
I hope, Edward Matias (second largest insider of the original Hovis Nano tech firm) who co-funded and co-founded, and co-managed the billion dollar Nasdaq Carlyle Group, et. al. is still pulling strings behind the scenes....
Because the last time I checked he was the COB of the U-Penn-Med Trust that controls about 10,000 patents and thus he has the connections to head hunt people and patents and find ways to commercialize them. He also started and ran a fully funded 100 Mil dollar, VC biotech investment firm in the summer of 2021.... But I doubt, he is any spring chicken eitehr, and the FED-eral Reserve has, as a side effect of its kill inflation policy, and damn any collateral damage, put the big hurt on funding the bio-tech research world, and start ups... So the pandemic lock downs, deaths, recent strokes (Hovis) and recent Dr. Kester Death, all why we have not yet gotten any farther than we are right now.
What I do not know, is what part of the Hovis Insiders gave the current CEO control, and what king of leash they may or may not have on him? Does he even know, 1/2 of what I figured out from the outside? He was just a hired gun, hired by Hovis to get a shell in 2019. And now, he is the reason were are still alive and saw the shell removed...
Hovis did not, by himself own enough common shares to control the company by himself after the 2020 changes. He and Mathias did. Mathias and about 3-4 others had enough common shares to out-vote Hovis, if needed, based on what all I read....
Hovis, had 36% of the common shares, and Mathias, about 24%, so they held the key cards.... I seriously doubt they just handed this company back to the custodian with one preferred vote control share with out some kind of leash, Money(?), a contract? whatever, to have some kind of say over he what does....
This CEO (Or who ever gets the NDTP emails) knows how to reach me, if he needs my help and wants to know what kind of people and patents and Nanotech I could bring to the company.
He has not...Which tells me they are working on the next steps now, using their own lists and connections (Mathias, et.al), and they know we are not to be screwed with...or miss treated.
They already found one deal from the EU, that we soundly rejected, for obvious good reasons...
We have a huge opportunity here with NDTP. Lets not screw it up....
Lets get the right people and add the right business plans and tech as needed... to make this a great Nano-Bio-tech firm
I believe you're correct about the CE cleanup. Finally.
Passalaqua ain't stupid. He was sitting on around $15 million in insider share value when NDTP was in the $4 range. But then Hovis screwed the pooch by not keeping the filings current and Passalaqua watched it all get pizzed away. Then it got worse under his stewardship. Then he lost a deal due to both the continuing CE drama, and the emergence of a loyal but vocal group of common shareholders who let him know we have a very strong legal case if he splits our shares beat down by his and Hovis' own filing incompetence. Deal off!
My guess is he's extremely motivated to get us out of CE hell now. I'll bet we lit a fire under his petard. But i'm really at a loss as to why the silence on our new daddy?
Exactly, Bob.
WTF is up?
Only Passalaqua and our new unknown Daddy know. And apparently we ain't one of the cool kids.
Yeah but....
If I was one of the DoNothing11, I'd hate to see my shares, which were originally valued at say, approx $4 a share, be bought back for $0.10 a share.
I'm a generous person, but not that generous.... and there would be serious tax consequences, no?
This still begs the question : W T F is going on!
The breakdown of who owns what is relatively simple:
As of 4/10/23 TA Update
Outstanding Shares 160,004,349
Restricted 159,712,185
---Unknown Daddy 155,316,868
---Passalaqua 3,872,550
---MILV/NDTP Insiders Holding Restricted Shares 304,349*
---Unknown but Possible Passalaqua Reimbursement for Paid Expenses 218,418
Unrestricted 292,164
*These insider shares could have been bought by Big Unknown Daddy as part of the deal to allow the Do Nothing 11 to exit in full.
I remember a couple of years back I had stink bids in and one day I was surprised to see a few shares in my account. Don r even remember how many shares I have now, not that many though.
The original Hovis group restricted shares issued was a 117 Million share lot
The recent added restricted shares was a 150 Million lot to an undisclosed party.
My best guess is they went to the UPennMed TBI Research Hospital.....
I am 99.9999% sure the eliminated shares came out of the 117 Million share lot, and was likely an equal % reduction.
I am expecting a second reduction of equal size of the 150 Mil share lot.
I am very tempted to swoop in and eat all the shares left at $1/share
Here is the restricted share breakdown:
March TA Update 273,498,116
April TA Update 159,712,185
Difference 113,785,931
Shares of the 11 non-Passalaqua Insiders 113,700,000
Difference 85,931
Old MILV Insiders Still Holding Restricted Shares 304,349
Difference 218,418
Possible Added Passalaqua Shares to Cover Expenses 218,418
New Unknown Insider Daddy Shares 155,316,868
The outstanding and restricted dropped by 113,785,931 shares, while the unrestricted stayed the same at 292,164.
Here's something very interesting. The 12 insiders had a total of 117,876,899 restricted shares before the whole Swiss company debacle. Then around 155 million shares were added to the restricted, but thus far Passalaqua has refused to announce where those 155 million shares came from.
But if you take the 117,876,899 previous insider shares and subtract Passalaqua's previously reported 3,872,550 shares, you get 114,004,349 shares, almost exactly the 113,785,931 that was dropped from the restricted as of this TA update. The difference is ony 218,418 shares.
So my deduction here is that the roughly 155 million shares added during the time of the Swiss company debacle remain, as does Passalaqua's shares. And the 11 other insiders are gone from the company like a fart in the wind. Passalaqua kept all his shares and perhaps granted himself an extra 218,418 shares for services rendered like fees paid and other operating expenses, and for retiring the 1 super majority voting share.
My question and the giant elephant in the room is... who is our new roughly 155 million share daddy? It is unconscionable that Passalaqua has not informed his common shareholders about who owns the 99.817% of our company. If this isn't disclosable material information required by the SEC then what the hell is? It is all well and good to believe this information will be disclosed on the Q1 filing, but a timely filing is far from a sure thing with this guy and this company based on past disappointments resulting in our current CE purgatory.
I'm the only one on the bid @ 10 cents and i didn't get any of those 17 shares. The market makers kept them. This has been happening a lot. They are filling their coffers @ my price. At least i'm forcing them to pay 10 cents instead of .0001
Did someone actually pay $1.70 for 17 shares today plus perhaps $5.95 brokerage fee,lol?
KabababBoom, When NDTP retail shareholders speak (or bark) the company listens.
I like it, I love it, I want some more of it...
Now the question is who got the last 150 Mil shares? And why? Time to spill the beans Mr CEO.. Who got them and why???
If you got them, time to return them (that is not a request, LOL). If UpennMed got them, time for their hair cut. I doubt UPennMed wants to be sued by noisy shareholders, or wants to be a stuck holder with 95% of the restricted shares, and no exit?
Love the progress, lets get this cleaned up, and solving TBI, Traumatic Brain Injury like we all started out to do..... or at least reversing some of the effects, limiting the damage... of TBI?
We have the public company, retail support, we have the technology, or at least some of it, and the rest can be licensed or bought.
I have accumulated and researched all the published research, spent >>5,000 man hours digging up the 40 year history behind the Nano Tech Fountain and Kester worked on, and all the others, and the most recent research, and this can be done in many safe ways, so lets get on with it....
You have retail shareholders willing to help... Right here.... If and when needed...
Thanks for listening to us!!!
Targeted Cancer nano particles called/based on Ceramide research that can target cancer cells.
I have copies of the Dr Mark Kester et. al. papers now. A lot more that I had last year...
Question is will the powers at the helm of NDTP-ville make a deal with some of his co-workers, collaborators researchers..., or follow through on what Hovis and UPennMed spent 7+ years working on.... Or something similar, or a combination...
There is a massive list of related NDTP opportunities, they can do something real with here, while they have loyal retail shareholders and the perfect place to do it..
If they can't do it, we will....
Some examples:
Hot off the press, Dr. Mark Kester Co-Author
https://cdn.discordapp.com/attachments/766667306699980810/1095512320811221022/Simultaneous_Inhibition_of_Ceramide_Hydrolysis_and.pdf
I am already an EGCG green tea extract fan.
This is a whole new level of why it works on the brain. (Original Dr. Michael Fountain/Hovis Univ Of Florida spin off)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417148/
(-)-Epigallocatechin-3-Gallate Protects Against Lithium-Pilocarpine...
Temporal lobe epilepsy (TLE) is the most common type of intractable epilepsy in humans, and it is often accompanied by cognitive impairment. In this study, we examined the effects of (-)-Epigallocatechin-3-gallate (EGCG) after SE on behavior in ..
The question I have, is who is pulling Mr. P's strings?
It is time they clean this mess up, and did something real. We have been patient for 3.5 years...
Pretending like Retail shareholders do matter was a huge mistake last month.
I hope they learned their lesson?
IMO, the 3 years of pandemic delays were for good reasons. Loosing Dr. Mark Kester last July was a huge loss to the world, not just NDTP.
If we need to wait a little longer, for the perfect new deal, fine... Replacing someone Like Dr. Kester, with the perfect people, does not happen over night.
But if they think they can dump 273 Mil shares on us with a last minute, rushed cook the books(?) scam, they are sorely mistaken.
This is not my first Rodeo...
Mark Kester upload mystery, eh? Well, you can always start with the source - will probably get a quicker response than from Mr. P.
Dr. Mark Kester
c/o Mount Hebron Cemetery
Internment #230049
Plot 3-14-E-1
PO Box 228
Flushing. NY 11352
Do you have an idea what is in the new papers - expressed in layman's simple terms ( for people like me)?
"I may look stupid, but I ain't ignorant"......
$NDTP's Dr. Mark Kester, who the news says past away last July(?) has uploaded a number of his research papers to research-gate and another site, academia.org , some that were just published last month.
Hmm, while some claim to have been uploaded by Dr. Mark Kester, some were uploaded by colleagues of his.., so it may be a computer glitch, as to who uploaded them...
I had asked for over 2 years for copies of some of them, but got crickets. Now all of a sudden the last 8 weeks, a number of them got uploaded....
Two $NDTP MM's are on the ask at $50.00/share
(psst....) shsss...
April 4th and all is quiet. Not even a peep...
$NDTP
Looks like some one is penny ante shorting or wash trading 1 share at a time to cover the 56 shares of remaining short interest before the end of the week (or is it just 36 shares of short interest now? LOL).
Or moving 1 share to kids and grand kids accounts, aka Smokin hoppium for 1 share accounts hoping to get 99 free shares, like the claimed to be cancelled Swiss deal was planning to do for an uplist to Nasdaq..., that when called out as a cook the books scam cancelled the deal and ran like scared rabbits, I would not object to my retail shares, getting increased 99X times and going from 10,000 shares to 990,000 shares, with no R/S, but that is pretty much a sign of BS games I will not stand for, when they should be busy licensing the game changer NDTP tech or making viable sell-able products with it next, instead of shell games.
The Liposomal and Phytosomal nano particle vitamins and supplements, of extracts market has exploded the last 4 years while Hovis diddled around.
NDTP has a non-shell ticker now, an NDTP nano technology, and 292,200 share float with awesome potential. We just need some one in charge that is not asleep at the wheel.. and that is not a scum bag, like so many OTC stocks get stuck with, that has public company experience and drug or drink or supplement product line experience or a real private firm, ready to merge and go public that could immediately commercialize the NDTP tech.
It is, IMO, time that NDTP showed us, or me with an NDA, specifically what they have, if they need help, moving forward, so I can get/bring the right companies, people, what ever they need to get this ship moving. If they do not need help, then it is time for them to stop playing games and shit or get off the pot.
EcoMike sorry I just saw you message from over a week ago. I’m still not a paid member here so I can reply privately but the magic number still remains unchanged 7703.
https://www.ndtpharmaceuticals.com is now not connected to a web domain.....
Are they re-doing the website now?
Be careful what one wishes for, as the Hovis insiders own 117 Mil shares they could dump on us because of the time running out to hold and because of the 150 Mil share dilution they have not disclosed who they belong to yet, while the new 150 Mil shares are likely trapped for ages. If the 150 Mil shares is one entity, say UPennMed(?), they are stuck holders, with over 50% of the OS until this goes to Nasdaq. And they got 1000 times more shares than they should have just like the Hovis group got, after they R/S retail.
If not UPennMed then who the fork got the 150 Mil mil new shares weeks ago. And why did they get them before the cancelled Swiss cook the books plan ran and hid, with out ever proving it had anything real or worth while?
No way OTC Markets removes the CE/EM and Pink Limited with out that being disclosed.
Why did OTC markets remove the shell status in less than 24 hours? That makes zero sense right now...
The saddest part of all this is apparently Passalaqua and the other 11 insiders either don't know or don't give a flip that their 65 or so common shareholders are loyal to a fault, and if given competent, honest leadership there is nothing we won't do to help the company going forward. With this tiny float, give us a reason to get excited by the technology and we could run the stock to $30+ in a snap. It would be easy because the number of shares Ecomike's group owns and/or controls could be something north of 60% of the 292,000 float, and none of us are selling. I won't say exactly but i myself are way over 10% of that, and i'll be a voracious buyer if i'm given a compelling reason to do so by management.
Hopefully they'll figure out how incredibly ready we are to support this stock with even more of our hard earned money.
Adding 155 million more restricted shares to our Outstanding and not announcing to the shareholders what this is for, or PR'ing this incredibly material event, is a major fiduciary violation by CEO Passalaqua that will get him in very serious trouble with the SEC.
If i were him i would move quickly to fulfil my fiduciary responsibilities to all NDTP stakeholders.
Under company profile - it states "NO" to being a shell. Looks kind of official.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |